Key regions: Brazil, India, Australia, United States, United Kingdom
Antiviral drugs have been a significant part of the pharmaceutical industry for decades. These drugs are used to treat viral infections by inhibiting the growth of the virus in the body. Finland's Antiviral Drugs market has seen substantial growth in recent years, driven by several factors.
Customer preferences: Customers in Finland prefer antiviral drugs that are effective, safe, and affordable. They also prefer drugs that have minimal side effects and are easy to administer. In addition, customers are increasingly interested in natural remedies and alternative treatments for viral infections.
Trends in the market: The Antiviral Drugs market in Finland has seen significant growth due to the increasing prevalence of viral infections, including influenza, hepatitis, and HIV. The market is also being driven by the development of new and innovative antiviral drugs that are more effective and have fewer side effects than traditional drugs. Furthermore, the COVID-19 pandemic has led to a surge in demand for antiviral drugs, particularly those that are effective against the SARS-CoV-2 virus.
Local special circumstances: Finland has a well-developed healthcare system that provides universal coverage to all citizens. This has led to increased access to antiviral drugs for patients in the country. Additionally, Finland has a high level of public trust in the pharmaceutical industry and regulatory authorities, which has helped to promote the use of antiviral drugs in the country.
Underlying macroeconomic factors: Finland has a strong economy with a high level of per capita income. This has led to increased spending on healthcare and pharmaceuticals in the country. In addition, Finland has a highly educated population with a strong focus on research and development, which has helped to drive innovation in the pharmaceutical industry. The country's favorable business environment and supportive government policies have also contributed to the growth of the Antiviral Drugs market in Finland.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
